EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer

被引：0
|
作者：
Roderich E. Schwarz
Niranjan Awasthi
Srivani Konduri
Danielle Cafasso
Margaret A. Schwarz
机构：
[1] UT Southwestern Medical Center,Department of Surgery, Division of Surgical Oncology
[2] UT Southwestern Medical Center,Department of Pediatrics, Division of Pediatric Critical Care Medicine
[3] The Cancer Institute of New Jersey,Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Divisions of Surgical Oncology and Surgical Sciences
来源：
Annals of Surgical Oncology | 2010年 / 17卷
关键词：
Vascular Endothelial Growth Factor; Proliferate Cell Nuclear Antigen; PDAC Cell; ASPC Cell; Tumor Tissue Section;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1442 / 1452
页数：10
相关论文
共 50 条
  • [21] Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
    Awasthi, Niranjan
    Zhang, Changhua
    Hinz, Stefan
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2013, 32
  • [22] A single nanoparticle for pancreatic cancer combination therapy
    Liu, Jenny
    Liao, Longyan
    Erazo, Kevin
    Terrab, Leila
    Johnson, Jeremiah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [23] The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
    Xu, Meng-Dan
    Liu, Lu
    Wu, Meng-Yao
    Jiang, Min
    Shou, Liu-Mei
    Wang, Wen-Jie
    Wu, Jing
    Zhang, Yan
    Gong, Fei-Ran
    Chen, Kai
    Tao, Min
    Zhi, Qiaoming
    Li, Wei
    ONCOGENESIS, 2018, 7
  • [24] Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer
    Miyazaki, J
    Tsuzuki, Y
    Matsuzaki, K
    Hokari, R
    Okada, Y
    Kawaguchi, A
    Nagao, S
    Itoh, K
    Miura, S
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (03) : 499 - 505
  • [25] The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer
    Meng-Dan Xu
    Lu Liu
    Meng-Yao Wu
    Min Jiang
    Liu-Mei Shou
    Wen-Jie Wang
    Jing Wu
    Yan Zhang
    Fei-Ran Gong
    Kai Chen
    Min Tao
    Qiaoming Zhi
    Wei Li
    Oncogenesis, 7
  • [26] Combination antiangiogenic and androgen deprivation therapy for prostate cancer: A promising therapeutic approach
    Nicholson, B
    Gulding, K
    Conaway, M
    Wedge, SR
    Theodorescu, D
    CLINICAL CANCER RESEARCH, 2004, 10 (24) : 8728 - 8734
  • [27] Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation
    Schwarz, Roderich E.
    Awasthi, Niranjan
    Konduri, Srivani
    Caldwell, Lauren
    Cafasso, Danielle
    Schwarz, Margaret A.
    CANCER BIOLOGY & THERAPY, 2010, 9 (08) : 632 - 639
  • [28] Is gemcitabine (GEM)-based combination therapy good for the treatment of advanced pancreatic cancer?
    Hao, Fulong
    Chen, Xinyang
    Li, Hancong
    Feng, Qingbo
    Hou, Yong
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (01) : 478 - 479
  • [29] Combination antiangiogenic and androgen deprivation therapy for prostate cancer: A promising therapeutic approach
    Nicholson, B
    Wedge, S
    Conaway, M
    Theodorescu, D
    JOURNAL OF UROLOGY, 2005, 173 (04): : 157 - 157
  • [30] Developing effective combination therapy for pancreatic cancer: An overview
    Miller, Aubrey L.
    Garcia, Patrick L.
    Yoon, Karina J.
    PHARMACOLOGICAL RESEARCH, 2020, 155
12345